ÂÜẠ̀ẨÂ×

Dr Felstead retired from the position of Vice President, Head of Clinical Research, Pharmatherapeutics Division, Pfizer Inc in April 2014. He joined Pfizer in 1989, having qualified in Medicine at Leeds University UK in 1982. Dr Felstead was appointed Head of Clinical Research in January 2009 with responsibility for research projects up to Proof of Concept (Phase IIa) in the following Therapeutic Areas: Neuroscience, Cardiovascular and Metabolic Disease, Anti-Infectives, Pain and Regenerative Medicine. Dr. Felstead previously served as Development Therapeutic Area Head for Allergy and Respiratory medicines through to Phase IIIb. As well as line management roles, Dr. Felstead also led multiple development project teams including the Viagra (sildenafil) team when the first pulmonary hypertension study was being designed, which led to the successful Revatio development program. From 2003-2007 he led the Celsentri/Selzentry (maraviroc) team through to successful transatlantic registration of this novel anti-retroviral medicine.

Since retirement Dr Felstead consults widely on various programmes for VC, Biotech, and Pharma. Dr Felstead is a member of Innovate UK, Biomedical Catalyst Late Stage Award committee, a member of AdALta Limited’s Scientific Advisory Board, acting CMO for Mironid, a non-executive director with MGB Biopharma and a member of Tricapital Group, which invests in emerging businesses in the Scottish Borders and neighbouring counties.